Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
On Wednesday, Eli Lilly won the FDAs approval for Zepbound (tirzepatide), the first-ever authorized treatment targeting two incretin hormone receptorsGIP and GLP-1for chronic weight management
Cardiovascular benefitsincluding reduced blood pressure and improved cholesterol profileswere also maintained in the continuous-use group
Typical Dosing Schedules Your doctor will map out a specific plan for you, but it helps to know what a standard progression looks like
Pricing reflects the business model, not the molecule
The approach could begin by prioritizing treatment for patients most likely to benefit from GLP-1 drugs to reach specific weight loss targets
If the injection is missed or delayed, backup contraception like condoms is recommended to prevent unintended pregnancy
US$ 21.95
US$ 22.22
US$ 23.55
